SGMO


Is Sangamo’s (SGMO) Stock Price Collapse Justified?

Sangamo’s (NASDAQ:SGMO) shares lost over a quarter of their value in the past two days, leaving investors at odds over when it will …

Sangamo (SGMO): TxCell Acquisition Would Strengthen SGMO’s Position as a Leader in the Field of of CAR-Treg Cell Therapy, Says CEO

Sangamo Therapeutics (NASDAQ:SGMO) and TxCell announced this morning that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, …

J.P. Morgan Weighs in on Sangamo Therapeutics Inc’s (SGMO) Collaboration with Kite

Sangamo Therapeutics Inc (NASDAQ:SGMO) has just announced a strategic collaboration with Gilead Sciences, Inc’s (NASDAQ:GILD) company Kite, and shares are putting together a massive …

Stock Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Names New Chief Medical Officer and Chief Business Officer

Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today key leadership appointments to strengthen the company’s clinical and commercial capabilities.

Stock Update (NASDAQ:SGMO): Sangamo Biosciences, Inc.’s Genome Editing Program for Hemoglobinopathies to Transfer to Biogen’s Spin-Off Bioverativ

Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ.

Stock Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Reports Third Quarter 2016 Financial Results

Sangamo Biosciences, Inc. (NASDAQ:SGMO) reported its third quarter 2016 financial results and provided an update on recent events and development timelines for its therapeutic …

Company Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Receives Orphan Drug Designation From The FDA For SB-FIX

Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced today that the U.

Cowen Optimistic on Sangamo Biosciences, Inc. (SGMO) Following 2Q:16 Results, Despite Recent Clinical Delays

Cowen analyst Ritu Baral was out with a favorable note on shares of Sangamo Biosciences, Inc. (NASDAQ:SGMO), after the biotech company released second-quarter results and provided …

Company Update (NASDAQ:SGMO): Sangamo Biosciences, Inc. Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II

Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced that the U.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts